GH001 Shows Promise as Rapid-Acting Therapy for Treatment-Resistant Depression: JAMA

These findings are published in the Journal of the American Medical Association (JAMA) Psychiatry in March 2026.

Standard antidepressants fail to achieve remission in over half of patients, creating a significant clinical gap for treatment-resistant depression (TRD) that is currently underserved by limited approved therapies; building on evidence that psychedelics like 5-methoxy-N,N-dimethyltryptamine (mebufotenin) provide rapid symptom relief, Dr Michael E. Thase from the Perelman School of Medicine at the University of Pennsylvania and his colleagues conducted the trial to evaluate the safety and efficacy of an individualized GH001 regimen for managing depressive symptoms in this challenging population.

In the phase 2b, 7-day, randomized, double-blind trial conducted at 16 European sites, 81 adults with treatment-resistant depression—defined by non-response to two to five antidepressants—received up to three escalating inhaled doses of synthetic mebufotenin (6, 12, and 18 mg) or placebo on a single day, excluding those with recent monoamine oxidase inhibitor use, to primarily evaluate the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores by day 8 using remote independent raters.

Key Clinical Findings of the Trial Include:

• Rapid Symptom Reduction: The trial showed that GH001-treated patients experienced a significant 15.2-point drop in depression ratings by day 8, whereas the placebo group saw virtually no change.

• Superior Remission Rates: Remarkably, the analysis found that 57.5% of the GH001 cohort achieved full clinical remission compared to 0% in the placebo group, resulting in a number needed to treat of just 2.

• Broad Clinical Benefit: Beyond depression, the investigation observed substantial improvements in secondary outcomes, including anxiety levels, global illness severity, and overall quality of life.

• High Tolerability Profile: Most treatment-emergent adverse events (TEAEs) were mild—such as nausea in 42.5% of subjects—with the report identifying no serious safety concerns or treatment discontinuations during the initial phase.

• Sustained Long-term Effects: Data from the open-label extension (OLE) indicated that 87% of initial remitters maintained their status at the six-month mark through infrequent follow-up treatments.

The results suggest that an individualized regimen of GH001 provides a rapid and substantial therapeutic effect, with a large effect size of -2.0 observed just one week after a single day of administration. This novel approach achieved clinical remission in over half of the treated patients, offering a potent alternative to existing interventions for treatment-resistant depression.

Thus, the trial concludes clinicians may find that the rapid onset of action and favorable safety profile of this inhaled treatment support its potential integration into the management strategies for patients facing persistent depressive episodes.

While the inherent psychoactive effects of mebufotenin present challenges for maintaining a perfect double-blind environment, future investigations involving more chronically ill populations and larger subgroups will help further clarify the long-term utility of this intervention.

Reference

Cubała WJ, Bajbouj M, Bauer M, et al. GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. Published online March 25, 2026.